Edwards Lifesciences exec sells 17,968 shares

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported open-market sales of company common stock.

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported open-market sales of company common stock. On May 15, 2026, he sold 8,000 shares indirectly through a 401(k) account at $81.8216 per share and 9,968 shares directly at $82.0732 per share. A footnote notes the directly held sale was executed in multiple trades with prices ranging from $81.975 to $82.260, and the reported price is a weighted average. After these transactions, he held 22,798.2532 shares directly, 30,969.5756 shares indirectly via the 401(k), and 121,756 shares indirectly in a trust.

Insider Trade Summary

Net Seller: 17,968 shares

Net Sell 3 txns

Insider BOBO DONALD E JR

Role CVP,Strategy/Corp Development

Sold 17,968 shs ($1.47M)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,968	$82.0732	$818K
Sale	Common Stock	8,000	$81.8216	$655K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 22,798.2532 shares (Direct); Common Stock — 30,969.5756 shares (Indirect, 401(k)); Common Stock — 121,756 shares (Indirect, By Trust)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Total shares sold: 17,968 shares Indirect sale via 401(k): 8,000 shares at $81.8216/share Direct sale: 9,968 shares at $82.0732/share +3 more

6 metrics

Total shares sold 17,968 shares Common stock sold on May 15, 2026

Indirect sale via 401(k) 8,000 shares at $81.8216/share Common stock sold on May 15, 2026

Direct sale 9,968 shares at $82.0732/share Weighted average price from multiple trades

Direct holdings after sale 22,798.2532 shares Common stock held directly after May 15, 2026

401(k) holdings after sale 30,969.5756 shares Indirect common stock via 401(k) after May 15, 2026

Trust holdings 121,756.0000 shares Indirect common stock held by trust as of May 15, 2026

Key Terms

open-market sale, weighted average sale price, 401(k), By Trust, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

401(k) financial

"nature_of_ownership": "401(k)""

A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.

By Trust financial

"nature_of_ownership": "By Trust""

indirect financial

"ownership_type": "indirect""

FAQ

What did Edwards Lifesciences (EW) executive Donald Bobo Jr. report in this Form 4?

He reported open-market sales of Edwards Lifesciences common stock. The filing shows two sales on May 15, 2026, plus updated direct and indirect holdings in a 401(k) plan and a trust after the transactions.

How many Edwards Lifesciences (EW) shares did Donald Bobo Jr. sell?

He sold a total of 17,968 common shares. This included 8,000 shares sold indirectly through a 401(k) account and 9,968 shares sold from directly held shares, all on May 15, 2026, in open-market transactions.

At what prices were the Edwards Lifesciences (EW) shares sold by Donald Bobo Jr.?

The 8,000 indirectly held shares were sold at $81.8216 per share. The 9,968 directly held shares were sold at a weighted average price of $82.0732 per share, from multiple trades between $81.975 and $82.260.

How many Edwards Lifesciences (EW) shares does Donald Bobo Jr. hold after these transactions?

After the reported sales, he held 22,798.2532 shares directly. He also held 30,969.5756 shares indirectly through a 401(k) account and 121,756 shares indirectly through a trust, as reflected in the filing.

What types of ownership are reported for Donald Bobo Jr.’s Edwards Lifesciences (EW) shares?

The filing shows both direct and indirect ownership. Directly, he holds common stock in his own name. Indirectly, he holds shares through a 401(k) plan and additional shares through a trust, each reported with separate post-transaction balances.

Does the Edwards Lifesciences (EW) Form 4 mention weighted average pricing for the share sales?

Yes. A footnote explains that one transaction was executed in multiple trades between $81.975 and $82.260 per share, and that the disclosed $82.0732 price represents the weighted average sale price for those combined trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBO DONALD E JR

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP,Strategy/Corp Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		S		9,968	D	$82.0732(1)	22,798.2532	D
Common Stock	05/15/2026		S		8,000	D	$81.8216	30,969.5756	I	401(k)
Common Stock								121,756	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)